Sabine Chlosta

Chief Medical Officer at Triumvira

Dr. Sabine Chlosta joined Triumvira as Chief Medical Officer in January 2018 and works on therapies with genetically modified T-cells for patients with liquid and solid tumors. Prior to Triumvira, Dr. Chlosta consulted for Aurora BioPharma, a start-up company developing CAR-T cells in solid tumors, and was previously Senior Medical Director at Merck & Co. where she played a key role in the development of their PD-1 inhibitor Keytruda® in Non-Hodgkin's Lymphoma and also oversaw trials in other indications. Earlier in her career, Dr. Chlosta was a Medical Director at Glycomimetics where she helped launch the company’s first trial in cancer. Dr. Chlosta started her career in industry as a Fellow in oncology drug development at Novartis overseeing clinical pharmacology trials with a small molecule and helped launch the CAR-T lymphoma program with Kymriah®. Dr. Chlosta is board-certified in pediatric hematology-oncology and in pediatrics. She completed post-graduate training in hematology-oncology at the combined program of Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College and in pediatrics at State University of New York at Downstate. Prior to entering clinical training in the United States, Dr. Chlosta was a visiting research Fellow in immunology at Harvard. Dr. Chlosta received her PhD degree in Immunology and Infectious Diseases and her MD degree from Free University and Charité Medical School Berlin.

Alle sessies door Sabine Chlosta

Educational Panel

ma, 11 feb 2019 9 a.m. - 10 a.m.
Shubert Complex